Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas
NCT07017790 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2025-06-12
Summary
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Conditions
Interventions
- OTHER
-
Amino-acid PET
Patients received 18-fluoroDopa then a PET exam
Sponsors & Collaborators
-
Central Hospital, Nancy, France
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-30
- Primary Completion
- 2025-07-01
- Completion
- 2025-08-30
Countries
- France
Study Locations
More Related Trials
-
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
NCT03370926 ·Status: UNKNOWN
-
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
NCT04461002 ·Status: COMPLETED
-
Noninvasively Predicting Gene Status of Glioma
NCT03102112 ·Status: UNKNOWN
-
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme
NCT01252459 ·Status: UNKNOWN ·Phase: PHASE2
-
Non Invasive IDentification of Gliomas With IDH1 Mutation
NCT01703962 ·Status: COMPLETED
-
Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over
NCT02892708 ·Status: COMPLETED ·Phase: PHASE3
-
Multimodal Imaging of Hypoxia in Gliomas
NCT03716986 ·Status: UNKNOWN ·Phase: NA
-
Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide
NCT06255249 ·Status: COMPLETED
-
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
NCT04540107 ·Status: RECRUITING ·Phase: PHASE1
-
18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme
NCT04588454 ·Status: UNKNOWN ·Phase: NA
-
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
NCT03952598 ·Status: SUSPENDED ·Phase: PHASE2
-
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
NCT05937776 ·Status: RECRUITING
-
18F-DOPA-PET in Planning Surgery in Patients With Gliomas
NCT02020720 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain
NCT06148207 ·Status: RECRUITING ·Phase: NA
-
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
NCT01579253 ·Status: UNKNOWN
-
11C-Methionine PET as Prognostic Marker of Gliomas
NCT02518061 ·Status: COMPLETED
-
Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma
NCT05970757 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
NCT01089244 ·Status: UNKNOWN
-
Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
NCT03102203 ·Status: UNKNOWN
-
Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology
NCT00330109 ·Status: UNKNOWN ·Phase: NA
-
Establishing Radiolabelled PSMA as a Target for Glioma Treatment
NCT05263466 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
NCT01801371 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas
NCT06499831 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
68Ga-citrate PET/MR Imaging for Glioma
NCT03335280 ·Status: TERMINATED
-
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
NCT04304300 ·Status: COMPLETED